StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)

Close on Nov 18, 2026Market cap $4.74BP/E –Yield –

Travere Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Travere Therapeutics's price to book ratio was 199.9× on Nov 11, 2026, against 43.1× a year earlier. Over the last 5 years it ranged from 1.7× to 254.5×, with a median of 13.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026199.9×+153.4
2025Dec 31, 202546.5×−41.9
2024Oct 31, 202488.3×+85.9
2023Dec 29, 20232.4×−11.0
2022Dec 30, 202213.4×+7.2
2021Dec 31, 20216.2×+1.5
2020Dec 31, 20204.6×+2.1
2019Dec 31, 20192.5×−0.4
2018Dec 31, 20182.9×+0.2
2017Dec 29, 20172.7×+0.4
2016Dec 30, 20162.3×−0.1
2015Dec 31, 20152.4×−236.3
2014Oct 31, 2014238.7×–

More Travere Therapeutics figures

See a number that looks wrong?